A study from Dana-Farber Cancer Institute reveals that patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range. The research was presented at the annual meeting of the American Society of Hematology. "This is good evidence that age alone should not limit who should get a transplant for MDS," said Gregory Abel, MD, MPH, a medical oncologist at Dana-Farber. "Calendar ...
Read More
No comments:
Post a Comment